GlaxoSmithKline’s (GSK) Hold Rating Reaffirmed at Shore Capital

Shore Capital reissued their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Thursday.

Other equities research analysts also recently issued reports about the stock. Deutsche Bank reiterated a hold rating and set a GBX 1,610 ($22.57) target price on shares of GlaxoSmithKline in a research report on Wednesday, October 11th. Jefferies Group lifted their target price on shares of GlaxoSmithKline from GBX 1,675 ($23.49) to GBX 1,700 ($23.84) and gave the stock a buy rating in a research report on Monday, October 16th. Goldman Sachs Group reiterated a buy rating and set a GBX 1,900 ($26.64) target price on shares of GlaxoSmithKline in a research report on Tuesday, October 17th. Morgan Stanley set a GBX 1,600 ($22.43) target price on shares of GlaxoSmithKline and gave the stock a sell rating in a research report on Wednesday, October 18th. Finally, JPMorgan Chase & Co. reiterated a neutral rating and set a GBX 1,570 ($22.01) target price on shares of GlaxoSmithKline in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company. GlaxoSmithKline has a consensus rating of Hold and an average price target of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (LON:GSK) traded down GBX 12.80 ($0.18) during trading on Thursday, hitting GBX 1,291 ($18.10). 11,683,099 shares of the company traded hands, compared to its average volume of 9,220,000. The company has a market cap of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($17.32) and a 12 month high of GBX 1,724.50 ($24.18).

GlaxoSmithKline (LON:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The company reported GBX 111.80 ($1.57) earnings per share (EPS) for the quarter, beating the consensus estimate of GBX 110.90 ($1.55) by GBX 0.90 ($0.01). The company had revenue of GBX 763.90 billion for the quarter. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%.

In other GlaxoSmithKline news, insider Sir Roy Anderson purchased 562 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was acquired at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Insiders have acquired a total of 581 shares of company stock valued at $743,284 in the last 90 days.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline’s (GSK) Hold Rating Reaffirmed at Shore Capital” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2018/02/09/glaxosmithklines-gsk-hold-rating-reaffirmed-at-shore-capital.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply